| Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ A Gronchi, AB Miah, AP Dei Tos, N Abecassis, J Bajpai, S Bauer, ... Annals of Oncology 32 (11), 1348-1365, 2021 | 699 | 2021 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 596 | 2018 |
| Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort S Smeland, SS Bielack, J Whelan, M Bernstein, P Hogendoorn, MD Krailo, ... European journal of cancer 109, 36-50, 2019 | 586 | 2019 |
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label … NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ... The Lancet Oncology 17 (10), 1396-1408, 2016 | 558 | 2016 |
| Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised … B Seddon, SJ Strauss, J Whelan, M Leahy, PJ Woll, F Cowie, ... The lancet oncology 18 (10), 1397-1410, 2017 | 469 | 2017 |
| Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay, N Abecassis, J Bajpai, S Bauer, R Biagini, S Bielack, ... Annals of oncology 33 (1), 20-33, 2022 | 380 | 2022 |
| Osteosarcoma HC Beird, SS Bielack, AM Flanagan, J Gill, D Heymann, KA Janeway, ... Nature reviews Disease primers 8 (1), 77, 2022 | 299 | 2022 |
| Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up SJ Strauss, AM Frezza, N Abecassis, J Bajpai, S Bauer, R Biagini, ... Annals of Oncology 32 (12), 1520-1536, 2021 | 287 | 2021 |
| Incidence and survival of malignant bone sarcomas in England 1979–2007 J Whelan, A McTiernan, N Cooper, YK Wong, M Francis, S Vernon, ... International journal of cancer 131 (4), E508-E517, 2012 | 286 | 2012 |
| UK guidelines for the management of bone sarcomas C Gerrand, N Athanasou, B Brennan, R Grimer, I Judson, B Morland, ... Clinical Sarcoma Research 6, 1-21, 2016 | 237 | 2016 |
| Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours NC Turner, SJ Strauss, D Sarker, R Gillmore, A Kirkwood, A Hackshaw, ... British Journal of Cancer 102 (7), 1106-1112, 2010 | 237 | 2010 |
| Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity SJ Strauss, L Maharaj, S Hoare, PW Johnson, JA Radford, S Vinnecombe, ... Journal of clinical oncology 24 (13), 2105-2112, 2006 | 200 | 2006 |
| Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma: a pilot study RE Windsor, SJ Strauss, C Kallis, NE Wood, JS Whelan Cancer 118 (7), 1856-1867, 2012 | 178 | 2012 |
| Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for … P Schöffski, J Sufliarsky, H Gelderblom, JY Blay, SJ Strauss, S Stacchiotti, ... The Lancet Respiratory Medicine 6 (6), 431-441, 2018 | 177 | 2018 |
| Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma SJ Strauss, F Morschhauser, J Rech, R Repp, P Solal-Celigny, PL Zinzani, ... Journal of clinical oncology 24 (24), 3880-3886, 2006 | 170 | 2006 |
| Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden P Peneder, AM Stütz, D Surdez, M Krumbholz, S Semper, M Chicard, ... Nature communications 12 (1), 3230, 2021 | 143 | 2021 |
| The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines SJ Strauss, K Higginbottom, S Jüliger, L Maharaj, P Allen, D Schenkein, ... Cancer research 67 (6), 2783-2790, 2007 | 131 | 2007 |
| Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts S Stacchiotti, AB Miah, AM Frezza, C Messiou, C Morosi, A Caraceni, ... ESMO open 6 (3), 100170, 2021 | 130 | 2021 |
| Large-scale profiling of kinase dependencies in cancer cell lines J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ... Cell reports 14 (10), 2490-2501, 2016 | 125 | 2016 |
| What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients C Rothermundt, JS Whelan, P Dileo, SJ Strauss, J Coleman, TW Briggs, ... British journal of cancer 110 (10), 2420-2426, 2014 | 108 | 2014 |
